Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
JAMA Cardiology|March 15, 2017
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension StudyMichael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
Journal of the American Heart Association|August 24, 2013
Coronary artery bypass graft surgery using the radial artery as a secondary conduit improves patient survivalJohn Lin, Wen Cheng, Lawrence S Czer, et al.
Journal of the American College of Cardiology|October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With HypercholesterolemiaMichael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|July 1, 2015
Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory SupportMorcos Awad, Lawrence S C Czer, Camelia Soliman, et al.
Journal of the International Neuropsychological Society : JINS|February 10, 2021
Long-Term Levels of LDL-C and Cognitive Function: The CARDIA StudyMatthew T Mefford, Ligong Chen, Cora E Lewis, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 28, 2024
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label StudiesFrederick J Raal, Robert A Hegele, Andrea Ruzza, et al.
Journal of the American College of Cardiology|May 9, 2020
Cognition After Lowering LDL-Cholesterol With EvolocumabBaris Gencer, François Mach, Jianping Guo, et al.
European Heart Journal|September 19, 2021
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trialKazuma Oyama, Robert P Giugliano, Minao Tang, et al.
European Journal of Preventive Cardiology|November 12, 2024
Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemiaAlbert Wiegman, Andrea Ruzza, G Kees Hovingh, et al.
American Heart Journal|December 31, 2023
Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trialErin A Bohula, Nicholas A Marston, Andrea Ruzza, et al.
Pageof 3